Janney Montgomery Scott LLC lifted its holdings in The Chemours Company (NYSE:CC – Free Report) by 22.4% during the first quarter, Holdings Channel reports. The fund owned 31,886 shares of the specialty chemicals company’s stock after buying an additional 5,843 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Chemours were worth $431,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors also recently bought and sold shares of the stock. SG Americas Securities LLC purchased a new position in Chemours during the first quarter valued at $822,000. Yousif Capital Management LLC grew its stake in shares of Chemours by 6.1% in the first quarter. Yousif Capital Management LLC now owns 61,418 shares of the specialty chemicals company’s stock worth $831,000 after acquiring an additional 3,510 shares in the last quarter. Farther Finance Advisors LLC increased its position in shares of Chemours by 170.7% in the 1st quarter. Farther Finance Advisors LLC now owns 2,290 shares of the specialty chemicals company’s stock valued at $30,000 after purchasing an additional 1,444 shares during the last quarter. UMB Bank n.a. raised its holdings in Chemours by 73.9% during the first quarter. UMB Bank n.a. now owns 2,231 shares of the specialty chemicals company’s stock worth $30,000 after purchasing an additional 948 shares in the last quarter. Finally, Matrix Trust Co lifted its stake in Chemours by 64.9% in the first quarter. Matrix Trust Co now owns 16,408 shares of the specialty chemicals company’s stock valued at $222,000 after buying an additional 6,456 shares during the last quarter. 76.26% of the stock is currently owned by hedge funds and other institutional investors.
Chemours Price Performance
Shares of NYSE:CC opened at $12.73 on Friday. The Chemours Company has a 52 week low of $9.13 and a 52 week high of $25.54. The firm’s 50 day moving average is $11.26 and its two-hundred day moving average is $14.14. The company has a current ratio of 1.75, a quick ratio of 0.83 and a debt-to-equity ratio of 7.01. The firm has a market capitalization of $1.90 billion, a P/E ratio of 63.63 and a beta of 1.65.
Chemours Dividend Announcement
The business also recently disclosed a dividend, which was paid on Monday, June 16th. Shareholders of record on Monday, May 19th were issued a dividend of $0.0875 per share. The ex-dividend date of this dividend was Friday, May 16th. This represents a yield of 3.17%. Chemours’s payout ratio is presently 175.00%.
Analysts Set New Price Targets
A number of equities research analysts have weighed in on the company. Mizuho set a $15.00 price objective on Chemours in a report on Tuesday, April 15th. UBS Group dropped their price objective on shares of Chemours from $18.00 to $17.00 and set a “buy” rating for the company in a research note on Wednesday, May 7th. Royal Bank Of Canada lifted their price target on shares of Chemours from $14.00 to $15.00 and gave the company an “outperform” rating in a research report on Thursday. Wall Street Zen lowered shares of Chemours from a “hold” rating to a “sell” rating in a report on Wednesday, May 21st. Finally, Truist Financial cut their target price on shares of Chemours from $27.00 to $22.00 and set a “buy” rating on the stock in a research note on Monday, April 14th. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Chemours currently has a consensus rating of “Hold” and an average price target of $17.33.
View Our Latest Analysis on CC
Insider Buying and Selling at Chemours
In other Chemours news, insider Damian Gumpel acquired 7,822 shares of the business’s stock in a transaction that occurred on Tuesday, June 3rd. The shares were purchased at an average price of $9.95 per share, with a total value of $77,828.90. Following the completion of the transaction, the insider owned 131,701 shares in the company, valued at $1,310,424.95. The trade was a 6.31% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Shane Hostetter purchased 4,450 shares of Chemours stock in a transaction on Monday, May 19th. The stock was bought at an average cost of $11.28 per share, with a total value of $50,196.00. Following the transaction, the chief financial officer directly owned 59,694 shares of the company’s stock, valued at approximately $673,348.32. The trade was a 8.06% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 25,672 shares of company stock worth $251,573. Company insiders own 0.47% of the company’s stock.
Chemours Company Profile
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.
See Also
- Five stocks we like better than Chemours
- What is the Dow Jones Industrial Average (DJIA)?
- Rigetti Computing: Cantor’s Bullish Call May Be Just the Start
- What is a Microcap Stock? Everything You Need to Know
- Big Bank Buybacks: Morgan Stanley, Citi, & Wells Fargo Lead
- Options Trading – Understanding Strike Price
- 3 Top Stocks Under $20 Riding the “Made in America” Wave
Want to see what other hedge funds are holding CC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Chemours Company (NYSE:CC – Free Report).
Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.